Vnitr Lek 2013, 59(10):872-873

Léčebný přístup k vysoce rizikové chronické lymfocytární leukemii: alogenní transplantace krvetvorných buněk je jedinou šancí na trvalé vyléčení - editorial

L. Smolej
IV. interní hematologická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph.D.

Received: May 3, 2013; Published: October 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Smolej L. Léčebný přístup k vysoce rizikové chronické lymfocytární leukemii: alogenní transplantace krvetvorných buněk je jedinou šancí na trvalé vyléčení - editorial. Vnitr Lek. 2013;59(10):872-873.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 110-118. Go to original source... Go to PubMed...
    2. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010: 481-488. Go to original source... Go to PubMed...
    3. Lysák D, Jindra P. Vysoce riziková chronická lymfocytární leukemie - charakteristika a léčebné možnosti. Vnitř Lék 2013; 59: 887-894. Go to PubMed...
    4. Delgado J, Duarte RF. Practical aspects of allogeneic hematopoietic cell transplantation for patients with poor-risk chronic lymphocytic leukemia. Scientific World Journal 2011; 11: 161-172. Go to original source... Go to PubMed...
    5. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-1755. Go to original source... Go to PubMed...
    6. Smolej L, Procházka V, Špaček M et al. Doporučení pro léčbu alemtuzumabem u chronické lymfocytární leukemie (CLL). Vnitř Lék 2012; 58: 232-236. Go to PubMed...
    7. Smolej L. The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs 2012; 21: 1009-1017. Go to original source... Go to PubMed...
    8. Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-3566. Go to original source... Go to PubMed...
    9. Smolej L, Doubek M, Špaček M et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL). Trans Hemat 2013; 2: 61-68.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.